Kornimate/medical-research-clean huggingface dataset:
intravesical thermochemotherapy with mitomycin-c

Conditions: Bladder Cancer

Summary: to investigate effect of intravesical mitomycin-c(mmc) applied with bladder wall thermotherapy system on reccurrence and progression status of intermediate and high risk non muscle invasive bladder cancer

before the application of tct, complete transurethral bladder tumour resection (turbt) was performed. re-turbt was conducted within 4 weeks for patients with initial t1 pathology. the first tct instillation was applied at 1mo following the turbt or the re-turbt. thermochemotherapy application and treatment schedule: the bladder wall tct (bwt) system (elmedical ltd, hod-hasharon, israel) was used as a conductive heating modality. mmc (40 mg; mmc kyowa hakko kogyo co., ltd., tokyo, japan) was mixed with 50 ml of 0.9% saline solution and applied using a disposable silicone 20fr 3-way tct catheter (unithermia catheter; elmedical ltd). in each session, the bladder was irrigated with mmc solution at 42°c-45°c for 45 min via the bwt system. the treatment schedule consisted of an initial 6-week instillation, followed by control cystoscopy and urine cytology in the 3rd month and monthly instillations up to 1 yr. urine cytology and cystoscopy were performed every three months. the samples were collected from the suspected areas during cystoscopy. at the end of the first year, control cystoscopy with random bladder biopsies was conducted. during the second year, routine controls were conducted every three months. subsequently, follow-ups were performed every six months. in case of development of any complication in a patient, tct was discontinued. before each instillation of tct, clear urine cultures were obtained from all patients. no prophylactic anticholinergic was administered prior to intravesical tct. if tur bt pathology was ta or t1 during the follow-up, it was accepted as a recurrence. if it was cis or t2, it was accepted as a progression. all adverse events observed during the study were recorded according to the common terminology criteria for adverse events (ctcae) version 4.0 \[9. all study protocols were approved by the local ethical committee at our institution. an informed consent was obtained from all patients.

Eligibility criteria:
inclusion criteria: * newly diagnosed or followed as recurrent intermediate-risk non muscle invasive non muscle invasive bladder cancer according to the criteria of european association of urology. * newly diagnosed or followed as recurrent high-risk non muscle invasive non muscle invasive bladder cancer according to the criteria of european association of urology. * pathology of urothelial carcinoma exclusion criteria: * low bladder capacity (\<150ml) * increased post voiding residual urine (\>150ml) * untreatable or uncontrollable urinary tract infection * history of urethral stricture * presence of bladder diverticula larger than 1 cm * pathology other than urothelial carcinoma * who (world health organization) performance status \> 2 * upper urinary tract urothelial carcinoma diagnosis

Keywords: thermochemotherapy bladder cancer
clinical trial evaluating efficacy and safety of one dose versus two doses of influenza vaccination

Conditions: Infection in Solid Organ Transplant Recipients

Summary: randomized, multicenter, open label trial to compare safety and efficacy of two doses stationary flu vaccination vs one doses in solid organ transplant recipients.

the purposes of this study are: 1. evaluate the efficacy and safety of a double dose of seasonal flu vaccine compared to a single dose. 2. determine the specific cellular immune response produced after the first and second vaccine doses of seasonal flu vaccine by in vitro stimulation of specific memory cells (a and b flu viruses). 3. evaluate the humoral immune response produced after one dose vs two doses of seasonal flu vaccine by the measure of serum antibody levels. 4. evaluate clinical efficacy of stationary flu vaccine in solid organ transplant recipients. 5. evaluate a long term cellular and humoral response(1 year) of seasonal flu vaccine. 6. characterize the genetic expression profile of immune response after the flu vaccine in solid organ transplant recipients by means of a genetic sub-study. 7. characterize the flu vaccine effect (one dose and two doses) through the antibody anti-hla(human leukocyte antigen), and its influence on the rejection rate in solid organ transplant recipients, by means of immunologic sub-study.

Eligibility criteria:
inclusion criteria: 1. solid organ transplant recipient. 2. 16 years or older. 3. more than 30 days after transplantation. 4. negative pregnancy test for women of childbearing potential 5. the patient must give informed consent exclusion criteria: 1. no written informed consent. 2. acute rejection within 15 days prior to vaccination. 3. pregnancy. 4. hypersensitivity to the active substance, any of the excipients and waste, for example: eggs, egg albumin, chicken proteins. 5. history of a previous serious reaction to immunization (eg guillain-barré syndrome).

Keywords: influenza solid organ transplant recipients
work-related musculoskeletal system disorders among female workers in hazelnut factory

Conditions: Musculoskeletal Strain; Pain; Occupational Problems; Work-related Injury

Summary: the aim of this study is to determine the prevalence of work-related musculoskeletal disorders in female workers in hazelnut factory. the secondary aim is to investigate the relationship between the musculoskeletal disorders severity and working posture, work related factor, psychosocial factor.


Eligibility criteria:
inclusion criteria: * age \>18 years, * had at least 12 months of continuous working experience in hazelnut selection. exclusion criteria: * having pregnancy, * working in a standing position or having a burden job, * having joint disease, gout, diabetes, and trauma during the last one year

Keywords: work-related musculoskeletal disorders hazelnut factory low back pain neck pain
the effect of hyperbaric chamber treatment on patients with diabetic retinopathy

Conditions: Does Hyperbaric Chaber Treatment Improve Diabetic Retinopathy

Summary: diabetic retinopathy (dr) is a common complication of diabetes and is divided into non proliferative dr and proliferative dr. the damage is caused by either macular edema, macular ischemia that can be followed by vascular proliferation. hyperbaric chamber treatment assists in increasing the amount of oxygen in the plasma and in the tissues and has been proven to be beneficial in treating different wounds in diabetic patients but its effect hasn't been tested in diabetic retinopathy yet. this study will recruit 40 diabetic patients who are scheduled for hyperbaric treatment due to different indications such as chronic wounds or radiation damages and who also have diabetic retinopathy. these patients will undergo opthalmic physical examination including fundus photography and oct (optical coherence tomography - optical ir retinal photography). screening for these patients will be conducted at the hyperbaric chamber at assaf harofe medical center for all diabetic patients prior to their first treatment.


Eligibility criteria:
inclusion criteria: inclusion criteria: 1. patients between ages 18-90 with diabetes type i or ii and diabetic retinopathy who are scheduled for hyperbaric treatment for other indications than dr. 2. patients who signed an informed consent form and agree to undergo an ophthalmic physical examination, fundus photography and oct prior to hyperbaric treatment and oct exam following every 10 treatments in hyperbaric chamber. total number of hyperbaric treatments will be conducted according to the main indication for which they have been assigned this treatment. exclusion criteria: 1. patients with carotid stenosis of more than 70% 2. anemia of \< 10mg/dl 3. patients with chest x ray pathology which cannot be admitted to hyperbaric chamber treatment. 4. patients with claustrophobia or that cannot decompress properly. 5. patients with any malignant disease 6. patients with inability to sign informed consent decompression treatment will last 90 minutes in 2 atmospheres pressure with 100% oxygen. -
70 vs 110 degree side-cut angles in femtosecond lasik

Conditions: Operative Incision

Summary: the purpose of this study is to compare 70 and 110 degree side-cut angles on the same patient undergoing femtosecond laser-assisted in situ keratomileusis (fs-lasik).

lasik has become the preferred corneal procedure to correct certain refractive errors. one of the major advancements in lasik has been the introduction of femtosecond laser technology for flap creation. several studies have compared microkeratome and femtosecond laser technology, showing superior accuracy and precision of flap dimensions in the latter. the femtosecond laser technology provides different parameters and settings that can be changed according to the surgeon's preference. one of such parameters is the side-cut angle. some of the most common side-cut angles used today include 45, 70, 90, and 110 degrees. previous studies have reported on the visual outcomes of side-cut angles, but head to head comparisons are lacking. currently, there are no studies comparing the safety and efficacy of the 70 and 110 side-cut angles in fs-lasik. information regarding the outcomes and complication rates between these side-cut angles will provide an objective measure that can be used when deciding which one is more suitable in fs-lasik. one angle will be performed on the right eye and the other on the left eye. the study will evaluate uncorrected visual acuity, best corrected visual acuity, intraoperative, and postoperative complications. performing different side-cut angles on the same individual will allow a direct comparison of outcomes, minimizing confounding variables.

Eligibility criteria:
inclusion criteria: * subjects who are deemed suitable candidates for bilateral lasik will be considered eligible for participation in this study. correction will be distance for both eyes. exclusion criteria: * selection will be consistent with current standard of care. any patient that is not a suitable candidate for lasik will not be included.

Keywords: femtosecond lasik (fs--lasik) visual acuity refractive errors side-cut angles
comparison and strategy optimization of plasma ebv dna and p85-ab with vca/ebna1-iga for screening nasopharyngeal carcinoma in high-risk areas

Conditions: Nasopharyngeal Carcinoma (NPC); Screening; Epstein Barr Virus

Summary: this study is a prospective, self-controlled, multicenter clinical trial. all participants will be tested for epstein-barr virus (ebv) associated biomarkers, including the two-antibody method (vca-iga and ebna1-iga), bnlf2b total antibodies (p85-ab), and plasma ebv dna. furthermore, novel screening biomarkers, such as next-generation sequencing for ebv and castoff cells using nasopharyngeal swabs, will be explored. first, it aims to investigate whether plasma ebv dna testing or the p85-ab testing can achieve higher sensitivity than the current standard two-antibody method testing while maintaining specificity in npc screening, thereby identifying the optimal initial npc screening strategy. based on the determined optimal initial screening strategy, the study will validate the proposed two-step method (subjects first undergo two-antibody method testing and p85-ab testing; those positive for either one biomarker above proceed to plasma ebv dna testing; subjects positive in both steps are defined as high-risk and receive endoscopic examinations with or without biopsy) compared with the single-step method (subjects simultaneously undergo two-antibody method testing, p85-ab testing, and plasma ebv dna testing; subjects with any positive biomarker undergo endoscopic examinations with or without biopsy) and each single screening testing. the aim is to determine whether two-step method can further improve the positive predictive value (ppv) while maintaining non-inferior sensitivity, thereby enhancing screening efficiency, reducing the rate of invasive procedures (such as endoscopic biopsies), and lowering medical costs and insurance burdens.


Eligibility criteria:
inclusion criteria: * voluntarily signed informed consent. * age between 30 and 69 years at the time of screening. * residents of guangdong province or guangxi province. * able to cooperate with long-term follow-up. exclusion criteria: * severe medical comorbidities, significant organ (heart, lung, liver, kidney) dysfunction, or psychiatric disorders. * severe autoimmune diseases or immunodeficiency. * history of or current malignant tumors. * inability to cooperate with the study due to psychological, social, familial, or geographical reasons.

Keywords: nasopharyngeal carcinoma (npc) screening epstein barr virus ebv dna ebv antibody
turkish version of life habits assessment

Conditions: Cerebral Palsy

Summary: cerebral palsy (cp) is the most common cause of physical disability in children, is a non-progressive neurological impairment resulting from an injury in the developing brain and causing various problems related to sensory, perception, cognition, and movement. this problems leads activity and participation levels of the children with cp. in the literature various assessment tools developed for assessing participation. assessment of life habits (life-h) questionnaire is one of the assessment tools that examines activities of daily life and participation in detail. the scale is originally in french but english and german versions are also available. the aim of this study is to translate the scale to turkish and to determine validity and reliability of turkish version of life habits questionnaire.


Eligibility criteria:
inclusion criteria: * to be diagnosed as cerebral palsy exclusion criteria: * children whose family didn't accept to participate to study

Keywords: cerebral palsy participation life habits (life-h) validity reliability
expanded access for cc-486

Conditions: Acute Myelogenous Leukemia (AML)

Summary: this is an expanded access program (eap) for eligible participants designed to provide access to cc-486.


Eligibility criteria:
inclusion criteria: -adult patients with documented acute myelogenous leukemia (aml) in their first complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment, who seek treatment with cc-486 as monotherapy to maintain their cr or cri. exclusion criteria: * patients with aml in cr/cri who plan to proceed to or are waiting for a bone marrow transplant * patients who have received a bone marrow transplant for the treatment of aml * treatment of aml patients with relapse or refractory disease * pregnant or breast-feeding females * patient meets enrollment criteria and can participate in a disease-specific clinical trial

Keywords: expanded access compassionate use
microneedle and trichloroaceticacid in treatment of melasma

Conditions: Melasma

Summary: melasma is an acquired disorder of hyperpigmentation characterised by blotchy, light-to-dark brown macules distributed symmetrically on the sun-exposed parts of the body. although many factors have been proposed to have a role in pathogenesis, the exact ethology is yet to be understood. the most commonly identifiable risk factors include ultraviolet radiation, genetic predisposition, pregnancy, oral contraceptives, thyroid disease and drugs like antiepileptic. the excessive pigmentation has been attributed to both melanocytosis (increased number of melanocytes) as well as melano genesis (excess production of melanin) as confirmed in a histopathological study on asian patients.\] furthermore, a vascular component has also been proposed to play a role in the pathogenesis of melisma. kim et al. have found that lesion melasma skin had greater expression of the vascular endothelial growth factor in keratinocytes compared to nearby nonlesional skin.

as regards management, the therapeutic options range from photoprotection, topical hypopigmenting agents, chemical peels and lasers. there are variety of less-tried systemic agents like fish oil, green tea and . although no single agent has proved to be effective for all patients, a combination of two or three agents is often tried to achieve optimum results. chemical peeling is the application of a chemical agent to the skin, which causes the controlled destruction of a part or of the entire epidermis, with or without the dermis, leading to exfoliation and removal of superficial lesions, followed by the regeneration of new epidermal and dermal tissues. chemical peels are a well-known modality of treatment for melasma. the basic mechanism of the action of chemical peels in melasma is the removal of unwanted melanin by causing a controlled chemical burn to the skin. trichlroacetic acid peeling has been the gold standard in chemical peeling for many decades. for superficial peels trichlroacetic acid 10% to 25% are used. some authors consider up to 35% trichlroacetic acid as also a superficial. skin microneedling is a technique predominantly used to improve the appearance of cutaneous scarring and photo damage. fine needles puncture the skin, resulting in increased dermal elastin and collagen, collagen remodelling, and thickening of the epidermis and dermis. additionally, skin needling creates small channels, which increase the absorption of topically applied preparations a property which has been used in various dermatological treatments.

Eligibility criteria:
inclusion criteria: * both sex will be included age range from 18- 50 yrs.' old patients with realistic expectations. exclusion criteria: * patients taking oral contraceptive pills. patients with history of polycystic ovary. pregnant and lactating females. patients with active infection. patients on isotretinoin. patients with history of keloids,or hypertrophic scars.
comparison of 2 lightweight y-meshes after laparoscopic sacrocolpopexy

Conditions: Pelvic Organ Prolapse

Summary: the purpose of the study is to determine the clinical cure rates of pelvic organ prolapse from subjects that had a robotic-assisted sacrocolpopexy using alyte y mesh and restorelle y smartmesh lightweight mesh.


Eligibility criteria:
inclusion criteria: * all patients who underwent robotic-assisted laparoscopic sacrocolpopexy between january 2007 to august 2011 using either alyte y-mesh or restorelle y-mesh exclusion criteria: * refusal to participate in our long-term outcome study

Keywords: robotic assisted laparoscopic sacrocolpopexy y mesh pelvic organ prolapse
feasibility study on the verafeye system

Conditions: Atrial Septal Defect; Atrial Fibrillation; Atrial Arrhythmia; Left Atrial Appendage Closure

Summary: the objective of the study is to evaluate the performance of the verafeye system in subjects entitled to undergo a standard of care ablation or closure procedure. results from this study will be used to guide development and refinement the verafeye system. the study is not designed to collect data for product approval and as such does not have a safety or efficacy endpoint.


Eligibility criteria:
key inclusion criteria: * subject is 18 to 80 years of age at the time of consent * subject is scheduled to undergo a standard of care, de-novo catheter-ablation procedure to treat typical afl or af; or left atrial appendage (laa)/ atrial septal defect (asd) closure procedure * subject is able to understand and willing to provide written informed consent key exclusion criteria: * any of the following within 6 months prior to enrolment: * cardiac surgery including coronary artery bypass grafting, ventriculotomy, atriotomy * thromboembolic event (stroke), transient ischemic attack (tia) or neurological disturbances * myocardial infarction * any surgical or percutaneous cardiac procedure including coronary intervention and cardiac ablation * dilated or hypertropic cardiomyopathy * any planned surgical or endovascular intervention within 30 days before or after the ablation, or laa/asd closure procedure. * any of the following cardiac conditions: * new york heart association (nyha) class iv * left ventricular ejection fraction (lvef) \< 30% * implanted with a cardiac rhythm management device (pacemaker, crt, icd, loop recorder) * presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation * active coronary ischemia, significant valvular heart disease, or hemodynamically significant congenital cardiac abnormality * body mass index (bmi) \> 40 kg/m2 * body weight \< 50kg * pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the ablation, or laa/asd closure procedure) * life expectancy less than 12 months * subjects who are currently enrolled in another study * subjects with a thrombus or pericardial effusion detected in the la/laa during standard of care imaging
pain neuroscience education for depression

Conditions: Chronic Low-back Pain; Depression

Summary: this study will look at the effects of pain neuroscience education on a depression outcome tool in patients with chronic low back pain.

pain and depression have been shown to be interrelated, especially chronic pain: people in chronic pain develop depression and people with depression develop chronic pain. in light of this coexistence it is not surprising that current best-evidence for depression and chronic pain shows significant overlap which includes primarily some type of cognitive intervention, aerobic exercise, and skilled delivery of medication including selective-serotonin-reuptake-inhibitors and/or membrane stabilizers. current best-evidence regarding musculoskeletal pain provides strong support for pain neuroscience education (pne) to positively influence pain ratings, dysfunction, and limitations in movement, pain knowledge and healthcare utilization. additionally, pne has shown to powerfully influence psychosocial issues that powerfully influence pain and depression: fear-avoidance and pain catastrophization. evidence is lacking in whether pne could also influence depression ratings. the purpose of this study is to examine the immediate effect of pne on pain, function, and depressive symptoms (using the patient health questionnaire - phq-9) in patients attending pt for chronic low back pain (lbp). this will be a pre- and post-intervention convenience sample of consecutive patients with chronic lbp (pain \> 6 months) meeting the inclusion criteria, attending outpatient pt. on initial examination, intake data and information will be collected prior to pne and immediately following pne.

Eligibility criteria:
inclusion criteria: * adults over the age of 18 * presenting at pt with a primary complaint of lbp * lbp being present for 6 months or more * fluent in english * willing to participate in the study. exclusion criteria: * are under age 18 (minor) * had undergone lumbar surgery * cannot read or understand the english language * presents with any cognitive deficits rendering them unsuitable for pne (i.e., stroke, traumatic brain injury, etc.) * decline to participate * present with a medical etiology (red flag) associated with their lbp.

Keywords: chronic low-back pain depression